The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.

ABSTRACT:

Background

Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

Methods

We retrospectively reviewed data from patients with metastatic or unresectable epithelioid sarcoma at the Peking University People's Hospital treated with irinotecan (50 mg/m²/d d_1-5 Q3W) in combination with Anlotinib (12 mg Qd, 2 weeks on and 1 week off) from July 2015 to November 2021.

Results

A total of 54 courses were administered. With a median follow up of 21.2 mo

SUBMITTER: Xie L 

PROVIDER: S-EPMC10838420 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature